The group's principle activity is to provide early advance identification of various cancers and other diseases, and to accelerate the new drug discovery process by applying its proprietary software to the development of proteomic and other biomarkers. The group's research areas include ovarian, breast and prostate cancer, and other diseases. The group's services include licensing, and new drug discovery analytical services. The group operates from United States.
